Theratechnologies Provides Business Update Related To Current Covid-19 Situation

Supply chain remains intact with ample inventory of commercial medicines Research and development activities currently progressing Company withdraws 2020 financial guidance until further notice Montreal, Canada – March 31, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today issued an update on the Company’s activities in relation to the current …Lire la suite

Visceral Fat Is A Predictor Of Liver Fibrosis And Fibrosis Progression In People Living With HIV

Montreal, Canada – March 11, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that Dr. Lindsay Fourman, from Harvard Medical School, presented data demonstrating that visceral fat is a clinical predictor of liver fibrosis and liver fibrosis progression in an oral presentation during CROI 2020. These …Lire la suite

Change To Theratechnologies Management

Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who …Lire la suite

Theratechnologies Announces Financial Results For Fiscal Year 2019

Montreal, Canada – February 25, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the year ended November 30, 2019. Fiscal Year 2019 Financial Highlights • Record revenue with net sales of US$63,216,000, up 39.8% from the previous year • Trogarzo® sales reach US$27,696,000, up …Lire la suite

Theratechnologies signs agreements with Massachusetts General Hospital and Dr. Steven Grinspoon

Montreal, Canada – February 4, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon towards the development of tesamorelin for the potential treatment  of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis …Lire la suite

Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020

Montreal, Canada – December 19, 2019 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today provided preliminary revenue estimates for its recently completed fiscal year 2019 and revenue guidance for fiscal year 2020.   Theratechnologies expects to report consolidated revenues of approximately US$63.3 million for fiscal year 2019 compared to US$45.2 …Lire la suite

Theratechnologies’ Oncology Platform Improves Efficacy and Tolerability of Docetaxel In Vivo and In Vitro

Absence of neutropenia after six treatment cycles   Improved efficacy and tolerability even at quarter dose of docetaxel   Montreal, Canada – December 13, 2019 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to report on new data presented today at the San Antonio Breast Cancer Symposium (SABCS).   …Lire la suite

Theratechnologies Starts Commercialization of New EGRIFTA SV™ in the United States

Montreal, Canada – November 25, 2019 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that EGRIFTA SVTM (2mg/vial) is now commercially available in the United States.   Our salesforce has started detailing the product to physicians today while the supply chain is being filled, and people living …Lire la suite